Evaluation of bupropion effects on cancer related fatigue in patients with cancer

Not Applicable

Completed

• Conditions: Cancer.; Malignant neoplasms; C00-C97

• Registration Number: IRCT201706191497N7
• Lead Sponsor: Vice Chancellor for Research,Isfahan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Inclusion criteria were at least 18 years old, having a diagnosis of cancer with survival expectancy greater than 6 months, having a cancer-related fatigue defined by a score 4 or more on a brief fatigue inventory (BFI) screening scale that ranged from 0 (none) to 10 (as bad as it can be), and hemoglobin more than 9 g/dl taken less than 4 weeks before enrollment.
The exclusion criteria were Karnofsky Performance Scale of <50, history of convulsive seizure, current use (within 6 weeks preceding participation) of erythropoietin, psycho stimulants or antidepressants, brain metastasis, history of fatigue prior to cancer diagnosis, any medical cause for fatigue identified on screening tests or a review of systems, hypersensitivity to bupropion and illiteracy.

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F). Timepoint: Before intervention and after 4 weeks. Method of measurement: Questionnaire.

Secondary Outcome Measures

Name	Time	Method
Quality of life. Timepoint: Before intervention and after 4 weeks. Method of measurement: Questionnaire.